DSIJ Mindshare

Stock under Rs 25: Add this stock to your watchlist as it gets green signal from USFDA

Market participants are advised to keep the stock on their watchlist for Monday.

Karan Dsij 0 8180 Article rating: 3.9

Going forward, the 16800 mark is expected to act as strong support for the index, and traders are advised to keep a close watch on this level. In addition, market participants should also keep an eye on the stock of

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Kiran Shroff 0 1338 Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

This pharma company trades higher after receiving final approval from US FDA for its new drug application

Shares of the company zoomed 8 per cent on getting the final nod for Ketorolac Tromethamine Injection.

Vishwesh Sanas 0 18793 Article rating: 4.1

Shares of the company zoomed 8 per cent on getting the final nod for Ketorolac Tromethamine Injection. 

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR